The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Open accessAbstract
BACKGROUND: Prophylactic factor replacement in patients with hemophilia B improves outcomes but requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) with a prolonged half-life was developed to reduce the frequency of injections required. METHODS: We conducted a phase 3, nonrandomized, open-label study of the safety, efficacy, and pharmacokinetics of rFIXFc for prophylaxis, treatment of bleeding, and perioperative hemostasis in 123 previously treated male patients. All participants were 12 years of age or older and had severe hemophilia B (endogenous factor IX level of ≤2 IU per deciliter, or ≤2% of normal levels). The study included four treatment groups: group 1 received weekly dose-adjusted prophylaxis (50 IU of rFIXFc per kilogram of body weight to start), group 2 received interval-adjusted prophylaxis (100 IU per kilogram every 10 days to start), group 3 received treatment as needed for bleeding episodes (20 to 100 IU per kilogram), and group 4 received treatment in the perioperative period. A subgroup of group 1 underwent comparative sequential pharmacokinetic assessments of recombinant factor IX and rFIXFc. The primary efficacy end point was the annualized bleeding rate, and safety end points included the development of inhibitors and adverse events. RESULTS: As compared with recombinant factor IX, rFIXFc exhibited a prolonged terminal half-life (82.1 hours) (P<0.001). The median annualized bleeding rates in groups 1, 2, and 3 were 3.0, 1.4, and 17.7, respectively. In group 2, 53.8% of participants had dosing intervals of 14 days or more during the last 3 months of the study. In groups 1, 2 and 3, 90.4% of bleeding episodes resolved after one injection. Hemostasis was rated as excellent or good during all major surgeries. No inhibitors were detected in any participants receiving rFIXFc; in groups 1, 2, and 3, 73.9% of participants had at least one adverse event, and serious adverse events occurred in 10.9% of participants. These events were mostly consistent with those expected in the general population of patients with hemophilia. CONCLUSIONS: Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B. (Funded by Biogen Idec; ClinicalTrials.gov number, NCT01027364.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationThe hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Self-citationBarriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationInhibitor development in haemophilia B: an orphan disease in need of attention
DiMichele, D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06657.x · Cited by 251
Prolonged activity of factor IX as a monomeric Fc fusion protein
Peters, R. T., Low, S. C., Kamphaus, G. D., Dumont, J. A., Amari, J. V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T. J., Merricks, E. P., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239665 · Cited by 196
Self-citationWhite, G. C., Beebe, A., & Nielsen, B. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657536 · Cited by 192
Whelan, S. F. J., Hofbauer, C. J., Horling, F. M., Allacher, P., Wolfsegger, M. J., Oldenburg, J., Male, C., Windyga, J., Tiede, A., Schwarz, H. P., et al. (2013) · Blood · doi:10.1182/blood-2012-07-444877 · Cited by 187
Negrier, C., Knobe, K., Tiede, A., Giangrande, P., & Møss, J. (2011) · Blood · doi:10.1182/blood-2011-02-335596 · Cited by 184
Santagostino, E., Negrier, C., Klamroth, R., Tiede, A., Pabinger-Fasching, I., Voigt, C., Jacobs, I., & Morfini, M. (2012) · Blood · doi:10.1182/blood-2012-05-429688 · Cited by 176
Shapiro, A. D., Ragni, M. V., Valentino, L. A., Key, N. S., Josephson, N. C., Powell, J. S., Cheng, G., Thompson, A. R., Goyal, J., Tubridy, K. L., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367003 · Cited by 173
Self-citationHAEMOPHILIA PROPHYLAXIS IN SWEDEN
Nilsson, I. M., Hedner, U. K. E., & Ahlberg, A. (1976) · Acta Paediatrica · doi:10.1111/j.1651-2227.1976.tb16525.x · Cited by 160
Inhibitors: resolving diagnostic and therapeutic dilemmas
DiMichele, D. (2002) · Haemophilia · doi:10.1046/j.1365-2516.2002.00626.x · Cited by 148
Chitlur, M., Warrier, I. A., Rajpurkar, M., & Lusher, J. M. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2009.02039.x · Cited by 146
Ewenstein, B. M., Joist, J. H., Shapiro, A. D., Hofstra, T. C., Leissinger, C., Seremetis, S. V., Broder, M., Mueller‐Velten, G., Schwartz, B. A., & Mononine Comparison Study Group (2002) · Transfusion · doi:10.1046/j.1537-2995.2002.00039.x · Cited by 100
(2005) · Wiley eBooks · doi:10.1002/9780470987124 · Cited by 77
Haemophilia B: Christmas disease
Giangrande, P. L. F. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.9.1517 · Cited by 48
Hemophilia: New Protein Therapeutics
Pipe, S. W. (2010) · Hematology · doi:10.1182/asheducation-2010.1.203 · Cited by 45
Recht, M., Pöllmann, H., Tagliaferri, A., Musso, R., Janco, R. L., & Neuman, W. R. (2011) · Haemophilia · doi:10.1111/j.1365-2516.2011.02436.x · Cited by 44
Clinical trial design in haemophilia
DiMichele, D., Blanchette, V. S., & Berntorp, E. E. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02824.x · Cited by 23
Investigational drugs for coagulation disorders
Mannucci, P. M., & Mancuso, M. E. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.798302 · Cited by 12
Treatment of Inhibitors in Hemophilia B
Brown, S. A. (2005) · Wiley eBooks · doi:10.1002/9780470987124.ch18 · Cited by 6
Cited by
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Self-citationFusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Metadata
- Authors
- Powell, J. S., Pasi, K. J., Ragni, M. V., Ozelo, M. C., Valentino, L. A., Mahlangu, J. N., Josephson, N. C., Perry, D., Manco-Johnson, M. J., Apte, S., Baker, R. I., Chan, G. C., Novitzky, N., Wong, R. S., Krassova, S., Allen, G., Jiang, H., Innes, A., Li, S., Cristiano, L. M., Goyal, J., Sommer, J. M., Dumont, J. A., Nugent, K., Vigliani, G., Brennan, A., Luk, A., & Pierce, G. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-12-12
- Volume
- 369
- Issue
- 24
- Pages
- 2313-2323
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1976624075
- Cited by
- 365
- References
- 28
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.